Northera (Droxidopa) Patent Expiration, LOE Window & CMS Spending

Northera (Droxidopa) by Lundbeck Na: Off-Patent Genericized (AB Competition), 11 AB generics, $20.4M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLundbeck Na
FDA Application & PathwayN203202 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors11
2024 CMS Total Public Spend$20.4M
2024 Medicare Part D Spend$19.1M
2024 Medicaid Spend$1.3M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 26.2% 2-yr change)